Overview

Pioglitazone and Insulin Resistance in ADT

Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
This study is being done to establish the mechanisms underlying insulin resistance (reduced insulin action that can lead to high blood sugar and maybe diabetes) in patients undergoing androgen deprivation therapy (ADT) for prostate carcinoma as well as to investigate the role of pioglitazone therapy in reduction/ reversal of that insulin resistance
Phase:
Phase 3
Details
Lead Sponsor:
State University of New York at Buffalo
Treatments:
Pioglitazone